Syngene International has announced the conclusion of the acquisition of a multimodal biologics manufacturing facility from Stelis Biopharma Ltd. as announced on 4 July 2023.

The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs. 617 crores adjusted from the earlier gross value of Rs. 702 crores. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma Ltd.

The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. It also includes a commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing.

This will support increased focus for Mammalian Drug Substance opportunities in the CDMO space. With its current installed capacity of 8,000 litres, the near term expanded capacity at 28,000 litres will make Stelis a significant player in the space.

The Unit was acquired effective 1st December 2023 on payment of Rs. 395 crores. The balance, subject to final adjustments, will be paid in December 2023 on completion of certain post-closing actions by Stelis Biopharma Ltd.